Clinical Trial Detail

NCT ID NCT02495103
Title Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

renal cell carcinoma

Therapies

Metformin + Vandetanib

Age Groups: adult

No variant requirements are available.